01 - Overview prepared by NICE

02 - Assessment Report prepared by BMJ-TAG

03 - Comments on the Assessment Report - Department of Health

04 - Comments on the Assessment Report - Glaxo Smith Kline

05- Comments on the Assessment Report - Lilly

06. Comments on the Assessment Report - PharmaMar

07 - Comments on the Assessment Report - Royal College of Nursing

08 - Comments on the Assessment Report - Target Ovarian Cancer

09 - Response to comments on the Assessment Report prepared by BMJ-TAG

10 - Supplementary tables from BMJ-TAG

11 - Tables restructures from BMJ-TAG

12 - Executive summary of technology manufacturer’s submission - Lilly (gemcitabine) 

13 - Executive summary of technology manufacturer’s submission - PharmaMar (trabectedin) 

14. – Patient Access Scheme submission from  PharmaMar

15 - Consultee submission - Ovacome 

16 - Consultee submission - Ovarian Cancer Action 

17 - Consultee submission - Royal College of Nursing

18- Consultee submission – Royal College of Physicians and others

19 - Consultee submission Target Ovarian Cancer

20 - Patient expert statement declaration - Tilean Clarke

21 - Patient personal statement

22 - Patient expert statement declaration - Wendy Fisher

23 - Clinical expert statement declaration - Professor Jonathan Ledermann

24 - Clinical expert statement declaration - Professor Charlie Gourley

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.